School of Medicine
Showing 481-500 of 1,546 Results
-
Bertil Glader
Stanford Medicine Professor of Pediatric Hematology/Oncology, Emeritus
Current Research and Scholarly InterestsHematology/Oncology, biology, and treatment of bone marrow failure disorders, hereditary coagulation disorders-clinical trials.
-
Greg Glasscock
Clinical Associate Professor, Pediatrics - Neonatology
Current Research and Scholarly InterestsNeonatal Endocrinology
-
Anna L Gloyn
Professor of Pediatrics (Endocrinology) and of Genetics
Current Research and Scholarly InterestsAnna's current research projects are focused on the translation of genetic association signals for type 2 diabetes and glycaemic traits into cellular and molecular mechanisms for beta-cell dysfunction and diabetes. Her group uses a variety of complementary approaches, including human genetics, functional genomics, physiology and islet-biology to dissect out the molecular mechanisms driving disease pathogenesis.
-
Neville H. Golden M.D.
Marron and Mary Elizabeth Kendrick Professor of Pediatrics, Emeritus
Current Research and Scholarly InterestsMy research has focused on the medical complications of adolescents with eating disorders. My specific area of study has been the etiology and implications of amenorrhea in adolescents with eating disorders, in particular the management of reduced bone mass and osteoporosis in anorexia nervosa.
-
Natalia Gomez-Ospina
Assistant Professor of Pediatrics (Genetics)
Current Research and Scholarly InterestsDr. Gomez-Ospina is a physician scientist and medical geneticist with a strong interest in the diagnosis and management of genetic diseases.
1) Lysosomal storage diseases:
Her research program is on developing better therapies for a large class of neurodegenerative diseases in children known as lysosomal storage disorders. Her current focus is on developing genome editing of hematopoietic stem cells as a therapeutic approach for these diseases beginning with Mucopolysaccharidosis type 1 and Gaucher disease. She established a genetic approach where therapeutic proteins can be targeted to a single well-characterized place in the genome known as a safe harbor. This approach constitutes a flexible, “one size fits all” approach that is independent of specific genes and mutations. This strategy, in which the hematopoietic system is commandeered to express and deliver therapeutic proteins to the brain can potentially change the current approaches to treating childhood neurodegenerative diseases and pave the way for alternative therapies for adult neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease
2) Point of care ammonia testing
She also works in collaboration with other researchers at Stanford to develop point-of-care testing for serum ammonia levels. Such device will greatly improve the quality of life of children and families with metabolic disorders with hyperammonemia.
3) Gene discovery
Dr Gomez-Ospina lead a multi-institutional collaboration resulting in the discovery of a novel genetic cause of neonatal and infantile cholestatic liver disease. She collaborated in the description of two novel neurologic syndromes caused by mutations in DYRK1 and CHD4.
For more information go to our website:
https://www.gomezospina.com/ -
Julie Good, MD
Clinical Professor, Anesthesiology, Perioperative and Pain Medicine
Clinical Professor (By courtesy), PediatricsCurrent Research and Scholarly InterestsJulie's academic interests include pediatric palliative care, pain and symptom management for children with life-threatening illness, medical acupuncture, and meaning in medicine (the humanistic side of doctoring)
